Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

senaparib (IMP4297)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Huadong Medicine, IMPACT Therap

Drug class:

PARP inhibitor

Related drugs:

BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	IMP4297 Sensitive: C2 – Inclusion Criteria IMP4297 Sensitive : C2	IMP4297 Sensitive: C2 – Inclusion Criteria IMP4297 Sensitive : C2
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	IMP4297 Sensitive: C2 – Inclusion Criteria IMP4297 Sensitive : C2	IMP4297 Sensitive: C2 – Inclusion Criteria IMP4297 Sensitive : C2
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	IMP4297 Sensitive: C3 – Early Trials IMP4297 Sensitive : C3	IMP4297 Sensitive: C3 – Early Trials IMP4297 Sensitive : C3
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	IMP4297 Sensitive: C3 – Early Trials IMP4297 Sensitive : C3	IMP4297 Sensitive: C3 – Early Trials IMP4297 Sensitive : C3
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	IMP4297 Sensitive: C3 – Early Trials IMP4297 Sensitive : C3	IMP4297 Sensitive: C3 – Early Trials IMP4297 Sensitive : C3
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	IMP4297 Sensitive: C3 – Early Trials IMP4297 Sensitive : C3	IMP4297 Sensitive: C3 – Early Trials IMP4297 Sensitive : C3